Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis.

BACKGROUND Currently, blockade of the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling pathway has been proved one of the most promising immunotherapeutic strategies against cancer. Several antibodies have been developed to either block the PD-1 or its ligand PD-L1 are under development. So far, a series of phase I trials on PD-1/PD-L1 antibodies for non-small cell lung cancer (NSCLC) have been completed, without reports of results from phase II studies. Thus, we sought to perform a meta-analysis incorporating all available evidences to evaluate the efficacy and safety of PD-1 or PD-L1 inhibition therapy. METHODS Electronic databases were searched for eligible literatures. Data of objective respond rate (ORR) and rate of adverse effects (AEs) with 95% confidence interval (CI) evaluated by immunohistochemistry (IHC) was extracted. The outcomes were synthesized based on random-effect model. Subgroup analyses were proposed. RESULTS In overall, ORR in the whole population with PD-1 blockage treatment is 22.5% (95% CI: 17.6% to 28.2%). Additionally, the rate of Grade 3-4 AEs is 16.7% (95% CI: 6.5% to 36.8%) and drug-related death rate is 2.5% (95% CI: 1.3% to 4.6%). As for patients with PD-L1 inhibition therapy, an overall ORR is 19.5% (95% CI: 13.2% to 27.7%). A higher rate of Grade 3-4 AEs (31.7%, 95% CI: 14.2% to 56.5%) is observed with a lower drug-related death rate (1.8%, 95% CI: 0.4% to 8.3%). In exploratory analyses of anti-PD-1 agents, we observed that greater ORR was presented in the median-dose cohort (3 mg/kg) than that of both low-dose (1 mg/kg) and high-dose (10 mg/kg) cohort (low-dose vs. median-dose: OR =0.12, P=0.0002; median-dose vs. high-dose: OR =1.47, P=0.18). CONCLUSIONS Anti-PD-1 and anti PD-L1 antibodies showed objective responses in approximately one fourth NSCLC patients with a tolerable adverse-effect profile. In addition, median-dose (3 mg/kg) might be a preferential dosage of anti-PD-1 agents.

[1]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Soefje,et al.  Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[3]  S. Gettinger,et al.  Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. , 2014 .

[4]  S. Gettinger,et al.  Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). , 2014 .

[5]  S. Gettinger,et al.  First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. , 2014 .

[6]  M. Dolled-Filhart,et al.  Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). , 2014 .

[7]  M. Dolled-Filhart,et al.  Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). , 2014 .

[8]  S. Gettinger,et al.  Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. , 2014 .

[9]  N. Rizvi,et al.  Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. , 2014 .

[10]  A. Rossi,et al.  Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients? , 2013, Cancer treatment reviews.

[11]  C. Drake,et al.  Molecular Pathways Molecular Pathways : Coexpression of Immune Checkpoint Molecules : Signaling Pathways and Implications for Cancer Immunotherapy , 2013 .

[12]  L. Sequist,et al.  Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). , 2013 .

[13]  S. Gettinger,et al.  A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). , 2013 .

[14]  R. Herbst,et al.  Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). , 2013 .

[15]  Tanja Cufer,et al.  Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. , 2013, European Journal of Cancer.

[16]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[17]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[18]  L. Sequist,et al.  Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). , 2012 .

[19]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[20]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[21]  J Zhang,et al.  ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer , 2011, Medical oncology.

[22]  Jae Jin Lee,et al.  The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). , 2010, Lung cancer.

[23]  U. Jian-zhong Effect of RRM1 and BRCA1 Expressions on Efficiency of Gemcitabine and Platinum in Patients with Advanced Non-Small Cell Lung Cancer , 2010 .

[24]  Liu Xiao-qing Correlation of expression of ERCC1/RRM1 with cisplatin combined with gemcitabine chemotherapy sensitivity and prognosis in non-small cell lung cancer , 2010 .

[25]  P. Zatloukal,et al.  Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Gregory J Riely,et al.  Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials , 2009, Clinical Cancer Research.

[27]  Robert Pirker,et al.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.

[28]  G. Gores,et al.  Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis , 2009, British Journal of Cancer.

[29]  R. Ramlau,et al.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Yang Jun-quan RRM1 Expression and Efficacy Analysis of Gemcitabine in Advanced Non-small Cell Lung Cancer , 2009 .

[31]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[32]  D. Mavroudis,et al.  Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine , 2008, British Journal of Cancer.

[33]  J. Allison,et al.  Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.

[34]  G. Bepler,et al.  RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Bauke Ylstra,et al.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.

[36]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[37]  G. Bepler,et al.  Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer , 2003, Oncogene.

[38]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[39]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.